| Sharynn D Hall, MD | |
|
1075 Chase Pkwy Ste B, Waterbury, CT 06708-2948 | |
| (203) 755-6311 | |
| (203) 755-6263 |
| Full Name | Sharynn D Hall |
|---|---|
| Gender | Female |
| Speciality | Medical Oncology |
| Experience | 27 Years |
| Location | 1075 Chase Pkwy Ste B, Waterbury, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538276118 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 230016 (Massachusetts) | Secondary |
| 207RH0003X | Internal Medicine - Hematology & Oncology | 41164 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Yale-new Haven Hospital | New haven, CT | Hospital |
| Waterbury Hospital | Waterbury, CT | Hospital |
| Charlotte Hungerford Hospital | Torrington, CT | Hospital |
| Saint Mary's Hospital | Waterbury, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Yale New Haven Hospital | 8325935018 | 37 |
| Yale University | 9436061736 | 2241 |
News Archive
Pfizer Inc has obtained a preliminary injunction halting sales of a generic quinapril product marketed by Teva Pharmaceuticals USA Inc., Ranbaxy Pharmaceuticals Inc., and Ranbaxy Laboratories Limited.
Iomai Corporation has announced that it has begun enrollment of a Phase 2 trial designed to test its vaccine patch for travelers' diarrhea in volunteers traveling to sites in Mexico and Guatemala.
A moderate increase in vancomycin-resistant enterococci (VRE) at one hospital can lead to a nearly 3 percent increase in VRE in every other hospital in that county, according to a study in the August issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC).
The increasing threat from emerging infectious diseases makes it imperative that countries prepare for rapid response and containment activities and for a worst-case scenario such as an influenza pandemic, the World Health Organization (WHO) has advised.
Recovering unnecessarily lost patient information is now a viable reality. Lost to follow up rates in clinical research trials can range from 20- 60%. As a result, patients who drop from a clinical trial and 'go missing' can impart a major set-back in pharmaceutical research. Failure to contact patients and obtain final closure data, or bring them back into the clinical trial (if the protocol allows) results in study delays, increased patient recruitment costs, compromised study data, and in some cases an insufficient amount of information to prove the safety and efficacy of a drug.
› Verified 2 days ago
| Entity Name | Yale University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205822236 PECOS PAC ID: 9436061736 Enrollment ID: O20031105000015 |
News Archive
Pfizer Inc has obtained a preliminary injunction halting sales of a generic quinapril product marketed by Teva Pharmaceuticals USA Inc., Ranbaxy Pharmaceuticals Inc., and Ranbaxy Laboratories Limited.
Iomai Corporation has announced that it has begun enrollment of a Phase 2 trial designed to test its vaccine patch for travelers' diarrhea in volunteers traveling to sites in Mexico and Guatemala.
A moderate increase in vancomycin-resistant enterococci (VRE) at one hospital can lead to a nearly 3 percent increase in VRE in every other hospital in that county, according to a study in the August issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC).
The increasing threat from emerging infectious diseases makes it imperative that countries prepare for rapid response and containment activities and for a worst-case scenario such as an influenza pandemic, the World Health Organization (WHO) has advised.
Recovering unnecessarily lost patient information is now a viable reality. Lost to follow up rates in clinical research trials can range from 20- 60%. As a result, patients who drop from a clinical trial and 'go missing' can impart a major set-back in pharmaceutical research. Failure to contact patients and obtain final closure data, or bring them back into the clinical trial (if the protocol allows) results in study delays, increased patient recruitment costs, compromised study data, and in some cases an insufficient amount of information to prove the safety and efficacy of a drug.
› Verified 2 days ago
| Entity Name | Trinity Health Of New England Provider Network Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003882812 PECOS PAC ID: 0941113567 Enrollment ID: O20031110000651 |
News Archive
Pfizer Inc has obtained a preliminary injunction halting sales of a generic quinapril product marketed by Teva Pharmaceuticals USA Inc., Ranbaxy Pharmaceuticals Inc., and Ranbaxy Laboratories Limited.
Iomai Corporation has announced that it has begun enrollment of a Phase 2 trial designed to test its vaccine patch for travelers' diarrhea in volunteers traveling to sites in Mexico and Guatemala.
A moderate increase in vancomycin-resistant enterococci (VRE) at one hospital can lead to a nearly 3 percent increase in VRE in every other hospital in that county, according to a study in the August issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC).
The increasing threat from emerging infectious diseases makes it imperative that countries prepare for rapid response and containment activities and for a worst-case scenario such as an influenza pandemic, the World Health Organization (WHO) has advised.
Recovering unnecessarily lost patient information is now a viable reality. Lost to follow up rates in clinical research trials can range from 20- 60%. As a result, patients who drop from a clinical trial and 'go missing' can impart a major set-back in pharmaceutical research. Failure to contact patients and obtain final closure data, or bring them back into the clinical trial (if the protocol allows) results in study delays, increased patient recruitment costs, compromised study data, and in some cases an insufficient amount of information to prove the safety and efficacy of a drug.
› Verified 2 days ago
| Entity Name | Yale New Haven Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336139500 PECOS PAC ID: 8325935018 Enrollment ID: O20040227000825 |
News Archive
Pfizer Inc has obtained a preliminary injunction halting sales of a generic quinapril product marketed by Teva Pharmaceuticals USA Inc., Ranbaxy Pharmaceuticals Inc., and Ranbaxy Laboratories Limited.
Iomai Corporation has announced that it has begun enrollment of a Phase 2 trial designed to test its vaccine patch for travelers' diarrhea in volunteers traveling to sites in Mexico and Guatemala.
A moderate increase in vancomycin-resistant enterococci (VRE) at one hospital can lead to a nearly 3 percent increase in VRE in every other hospital in that county, according to a study in the August issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC).
The increasing threat from emerging infectious diseases makes it imperative that countries prepare for rapid response and containment activities and for a worst-case scenario such as an influenza pandemic, the World Health Organization (WHO) has advised.
Recovering unnecessarily lost patient information is now a viable reality. Lost to follow up rates in clinical research trials can range from 20- 60%. As a result, patients who drop from a clinical trial and 'go missing' can impart a major set-back in pharmaceutical research. Failure to contact patients and obtain final closure data, or bring them back into the clinical trial (if the protocol allows) results in study delays, increased patient recruitment costs, compromised study data, and in some cases an insufficient amount of information to prove the safety and efficacy of a drug.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sharynn D Hall, MD Po Box 808, Nashua, NH 03061-0808 Ph: (603) 578-5054 | Sharynn D Hall, MD 1075 Chase Pkwy Ste B, Waterbury, CT 06708-2948 Ph: (203) 755-6311 |
News Archive
Pfizer Inc has obtained a preliminary injunction halting sales of a generic quinapril product marketed by Teva Pharmaceuticals USA Inc., Ranbaxy Pharmaceuticals Inc., and Ranbaxy Laboratories Limited.
Iomai Corporation has announced that it has begun enrollment of a Phase 2 trial designed to test its vaccine patch for travelers' diarrhea in volunteers traveling to sites in Mexico and Guatemala.
A moderate increase in vancomycin-resistant enterococci (VRE) at one hospital can lead to a nearly 3 percent increase in VRE in every other hospital in that county, according to a study in the August issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC).
The increasing threat from emerging infectious diseases makes it imperative that countries prepare for rapid response and containment activities and for a worst-case scenario such as an influenza pandemic, the World Health Organization (WHO) has advised.
Recovering unnecessarily lost patient information is now a viable reality. Lost to follow up rates in clinical research trials can range from 20- 60%. As a result, patients who drop from a clinical trial and 'go missing' can impart a major set-back in pharmaceutical research. Failure to contact patients and obtain final closure data, or bring them back into the clinical trial (if the protocol allows) results in study delays, increased patient recruitment costs, compromised study data, and in some cases an insufficient amount of information to prove the safety and efficacy of a drug.
› Verified 2 days ago
Dr. Juan Fica, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 1389 W Main St, Tower 2, Suite 320, Waterbury, CT 06708 Phone: 203-753-9313 Fax: 203-573-8976 | |
Mrs. Kanthimathi Jegathesan, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2271 East Main Street, Waterbury, CT 06705 Phone: 203-753-4131 Fax: 203-753-6887 | |
Robert J Mcdonald, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 170 Grandview Avenue, Waterbury, CT 06708 Phone: 203-759-3666 Fax: 203-759-3671 | |
Dr. Lydia Aoun-barakat, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 140 Grandview Ave, Suite #l01, Waterbury, CT 06708 Phone: 203-574-4187 Fax: 203-591-1453 | |
David G. Hill, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 170 Grandview Avenue, Waterbury, CT 06708 Phone: 203-759-3666 Fax: 203-759-3671 | |
Shehryar Khaliqdina, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 56 Franklin St, Waterbury, CT 06706 Phone: 203-709-8685 | |
Dr. Joseph D Scuderi, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 56 Franklin St, Waterbury, CT 06706 Phone: 203-709-6000 |